Xeomin injections compared with placebo for focal hand dystonia
Tests Xeomin injections against placebo in adults with focal hand dystonia.
Key facts
- Who runs it
- Alain Kaelin
- Where
- Switzerland5 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 48 people, planned
- Started
- 21 Feb 2018
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Xeomin
- Placebo - Concentrate
- Record updated
- 19 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with focal hand dystonia, a condition causing involuntary cramping or twisting in the hand. It compares IncobotulinumtoxinA (Xeomin) injections with placebo.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Focal hand dystonia diagnosed by a neurologist specialized in movement disorders. Both idiopathic (no known cause) and secondary forms can join.
- Earlier treatment
- People never treated before and people treated before with other BoNT-A can join. The last BoNT-A treatment must be at least 3 months before joining.
Main reasons for not taking part
- Spasticity, other brain or spinal lesion of the motor system, or a nerve injury in the affected limb
- Allergy to BoNT-A toxins, including IncobotulinumtoxinA
- Pregnancy or breastfeeding
- Severe depression (>29 on the Beck Depression Inventory) or other relevant psychiatric disorder
- Another study with an investigational drug in the 30 days before or during this study
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Informed Consent as documented by signature
- Age ≥ 18 years
- Focal hand dystonia (FHD). Diagnosis must be made by a neurologist specialized in movement disorder (at least 2 years specific training, all partners listed have at least 2 years training)
- Both idiopathic and secondary FHD are allowed
- Both drug naive subjects and subjects previously treated with other BoNT-A will be included
- Patients must be willing and able to comply with the study procedures
- Female patients of childbearing potential must agree to use an effective method of contraception during the treatment period
Who cannot take part
- Doses and schedules of any ongoing treatment with potential confounding drugs such as muscle relaxants (for example Tolperison, Tizinadid, Baclofen, Mestinon, Dantrolen), benzodiazepine, neuroleptics or antidepressants have to be kept unchanged throughout the study and no changes should be made between the first trial injection and the end of study visit at week 12
- Previous treatment with other BoNT-A less than 3 months before the inclusion in this study
- Participation in another study with investigational drug within the 30 days preceding and during the present study
- Previous enrolment into the current study
- Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to BoNT-A toxins including IncobotulinumtoxinA
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
- Severe depression (>29 as measured with the Beck Depression Inventory, see Appendix 8) or other relevant psychiatric disorder
- INR > 2 on the day of injection if the patient is anticoagulated. If INR > 2, the study injection will be delayed until the return to a safer INR
- Presence of spasticity, or other central sensorimotor lesion of motor system other than dystonia in the affected limb
- Peripheral nerve lesion (diagnosis either clinical or electrophysiological) in the affected limb, for example with a muscle weakness at baseline
- Women who are pregnant or breast feeding,
- Enrolment of the investigator, his/her family members, employees and other dependent persons
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a multicenter, double-blind, randomized placebo controlled, parallel group, superiority trial in order to test the superiority of intramuscular injections of IncobotulinumtoxinA against placebo using a 1:1 allocation ratio.
The 2 groups in the trial
- Xeomin®Existing treatment, for comparison
Intramuscular IncobotulinumtoxinA (Xeomin®) injection under guidance (EMG and/or sonographic monitoring), 2.5 to 40 U in each muscle (max. 5 forearm- and/or hand muscles).
- Placebo concentratePlacebo, for comparison
Intramuscular Placebo injection under guidance (EMG and/or sonographic monitoring), in each muscle (max. 5 forearm- and/or hand muscles).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia: a Double-blind Placebo-controlled Randomized Multicenter Study: The "SwissHandSpasm" Study
- Plain-language title
- Xeomin injections compared with placebo for focal hand dystoniaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 19 March 2026